London IPO fundraising hits a three-decade low in another blow to the UK capital

London IPO fundraising plummeted to a three-decade low in the first half of 2025, with just five debuts raising £160 million, significantly underperforming the U.S. market and even post-2008 crisis levels. This sharp decline, exacerbated by companies like Wise moving primary listings and others abandoning London IPO plans, underscores growing concerns about the city's diminishing allure as a global capital hub. While some analysts attribute part of the slowdown to broader global IPO trends and see potential for London's recovery given recent regulatory reforms and renewed interest from select firms like Visma, the data highlights the critical challenge facing the U.K.'s equity markets.

Analysis

Fundraising from London IPOs collapsed to a three-decade low in the first half of 2025, with just five debuts securing a total of £160 million, according to Dealogic data. This performance is notably weaker than the £222 million raised in the immediate aftermath of the 2008 financial crisis and stands in stark contrast to the U.S. market, which saw 156 IPOs raise $28.3 billion in the same period. The negative trend is not confined to new listings; it is amplified by significant capital flight, evidenced by British fintech Wise moving its primary listing to New York and reports that AstraZeneca, the most valuable company on the FTSE 100, is considering a similar move to access deeper capital markets. The cancellation of planned listings by firms like Shein and Cobalt Holdings further underscores the diminishing appeal of the U.K. market. While some analysts point to a broader global slowdown in IPOs and potential for a rebound fueled by U.K. regulatory reforms, the combination of historically low fundraising volumes and high-profile corporate departures signals a critical challenge to London's status as a global financial hub.

Key Decisions for Investors

• Investors should review their exposure to U.K. financial sector assets and domestically-focused equities, as the persistent capital flight and anemic IPO pipeline signal underlying structural weaknesses.
• Monitor developments regarding AstraZeneca's potential relisting to the U.S., as such a move by the FTSE 100's largest constituent would have a material negative impact on index tracker funds and overall U.K. market sentiment.
• Watch for tangible evidence that recent regulatory reforms are successfully attracting high-growth international listings, such as the planned debut of Visma, as this could signal a potential inflection point and a contrarian opportunity in the U.K. market.